National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Liver Cancer

Primary liver cancer is a disease that occurs when malignant (cancer) cells form in the tissues of the liver. Most primary liver cancers begin in hepatocytes (liver cells). This type of cancer is called hepatocellular carcinoma or malignant hepatoma.

In advanced cases, liver cancer cells may invade surrounding tissues or spread (metastasize) to other parts of the body via the blood stream or lymph system.

It's common for other types of cancer to spread (metastasize) to the liver from other parts of the body. When this happens, the disease is not liver cancer. Instead, the cancer in the liver is named for the organ or the tissue in which it began. For example, colon cancer that spreads to the liver is metastatic colon cancer. It is not liver cancer.

In the United States, metastatic cancer in the liver is far more common than primary liver cancer.

It is estimated that 30,640* people in the United States will be diagnosed with liver cancer (including intrahepatic bile duct cancers) in 2013. More than 80 percent of these cases are primary liver (hepatocellular) cancer.

Treatment options for liver cancer vary depending on the stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Liver Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with liver cancer. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Liver Cancer
Phase II
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
NCI-11-C-0181, NCT01375569

Principal Investigator:Referral Contact:
Tim F. GretenSuzanne Fioravanti
301-451-4723301-594-6544
fioravas@mail.nih.gov
Phase I/II
A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)
NCI-11-C-0102, NCT01306058

Principal Investigator:Referral Contact:
Tim F. GretenSuzanne Fioravanti
301-451-4723301-594-6544
fioravas@mail.nih.gov


  
Trial and Protocol Number
Pediatric Cancers
Phase II
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
NCI-12-C-0098, NCT01502410

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Solid Tumor
Phase II
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers
NCI-10-C-0166, NCT01174121

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
NCI-13-C-0046

Principal Investigator:Referral Contact:
Electron KebebewErinn M. Hopkins
301-496-5049301-496-6457
erinn.hopkins@nih.gov
Phase I
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors
NCI-10-C-0113, NCT01120288

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
No Phase
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
NCI-12-C-0175, NCT01658917

Principal Investigator:Referral Contact:
Udai KammulaCarole Webb
301-435-8606301-402-8475
Webbcc@mail.nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111, NCT00452946

Principal Investigator:Referral Contact:
Deborah E. CitrinSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov